Home › Funds › Spruce Street Capital LP › LXEO
Spruce Street Capital LP position in LXEO
LEXEO THERAPEUTICS INC · Health Care
Spruce Street Capital LP reported holding 928,593 shares of LXEO (LEXEO THERAPEUTICS INC) in its Q3 2026 13F filing — a position valued at US$3.1M, representing 0.50% of its reported portfolio and ranking #35 among its reported holdings. Spruce Street Capital LP has disclosed LXEO holdings in 4 of the last 4 reported quarters, going back to Q4 2025.
Last updated: 2026-11-14 · Source: SEC EDGAR Form 13F-HR
How Spruce Street Capital LP's LXEO position evolved
Spruce Street Capital LP first disclosed a stake in LXEO in Q4 2025 at 175,000 shares (US$1.7M). The position peaked in Q1 2026 at 928,593 shares, worth US$5.3M. Across 4 filings, Spruce Street Capital LP increased the stake 1 time(s), trimmed it 0 time(s) and left it unchanged 2 time(s). The most recent filing (Q3 2026) shows 928,593 shares valued at US$3.1M. Notable position changes include a 431% increase in Q1 2026 (shares fell 19% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q4 2025 | 175.00K | $1.74M | New |
| Q1 2026 | 928.59K | $5.33M | Add |
| Q2 2026 | 928.59K | $4.32M | Hold |
| Q3 2026 | 928.59K | $3.14M | Hold |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About LXEO and 13F data
LXEO (LEXEO THERAPEUTICS INC) is a Health Care company. 37 other funds we track also report a position in LXEO — the largest reported positions include MONTANOVA CAPITAL, LLC (US$29.7M), Affinity Asset Advisors, LLC (US$24.5M), Frazier Life Sciences Management, L.P. (US$22.5M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding LXEO
- MONTANOVA CAPITAL, LLC 6.38M sh · $29.72M · Q2 2026
- Affinity Asset Advisors, LLC 7.25M sh · $24.49M · Q3 2026
- Frazier Life Sciences Management, L.P. 4.82M sh · $22.46M · Q2 2026
- Vestal Point Capital, LP 4.32M sh · $20.11M · Q2 2026
- Paradigm Biocapital Advisors LP 4.18M sh · $19.44M · Q2 2026
- 683 Capital Management, LLC 1.88M sh · $8.73M · Q2 2026
- Avoro Capital Advisors LLC 1.49M sh · $6.93M · Q2 2026
- Jones Hill Capital LP 593.74K sh · $2.01M · Q3 2026
- DAFNA Capital Management LLC 377.06K sh · $1.76M · Q2 2026
More on Spruce Street Capital LP
FAQ
How long has Spruce Street Capital LP held LXEO?
Spruce Street Capital LP has disclosed LXEO holdings in 4 of the last 4 reported quarters, going back to Q4 2025.
What is Spruce Street Capital LP's current position in LXEO?
As of Q3 2026, Spruce Street Capital LP holds 928.59K shares of LXEO (LEXEO THERAPEUTICS INC), valued at $3.14M, representing 0.50% of its reported portfolio and ranking #35.
Has Spruce Street Capital LP been buying or selling LXEO?
In the latest 13F filing (Q3 2026), Spruce Street Capital LP held unchanged its position in LXEO. The position peaked in Q1 2026 at 928.59K shares.
Which other funds hold LXEO?
Other major institutional holders of LXEO include MONTANOVA CAPITAL, LLC, Affinity Asset Advisors, LLC, Frazier Life Sciences Management, L.P., among 37 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.